^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tevimbra (tislelizumab) (PD1 inhibitor) + sitravatinib (MGCD516) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab en combinación con sitravatinib en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico
Excerpt:
...Able to provide archival/fresh tumor tissues for biomarker analysis to assess PD-L1 expression and other biomarkers. ...
Trial ID:
Source:
Title:
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Excerpt:
...Able to provide archival/fresh tumor tissues for biomarker analysis to assess PD-L1 expression and other biomarkers....
Trial ID:
Less C2 evidence
Source:
Title:
EP08.01-071 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Published date:
07/12/2022
Excerpt:
Sitravatinib plus tislelizumab showed a manageable safety and tolerability profile and demonstrated antitumor activity in patients with PD-L1+, locally advanced or metastatic non-squamous NSCLC who had not received prior systemic treatment in the metastatic setting.
Trial ID:
Source:
Title:
EP08.01-070 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Published date:
07/12/2022
Excerpt:
Confirmed ORR was 30.4% (95% confidence interval [CI]: 13.2, 52.9), with all seven patients achieving partial response. DCR was 78.3% (95% CI: 56.3, 92.5), median PFS was 5.4 months (95% CI: 2.8, 8.6), and median OS was not reached (95% CI: 6.7, not estimable). Sitravatinib plus tislelizumab demonstrated a manageable safety and tolerability profile as well as antitumor activity in patients with PD-L1+, locally advanced or metastatic squamous NSCLC who had not received prior systemic treatment in the metastatic setting.
Trial ID:
Source:
Title:
WS08.15 - Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Published date:
07/12/2022
Excerpt:
Between Jan 14, 2019, and Jun 18, 2021, 96 patients (pts) were enrolled and 13 pts were excluded due to inclusion violations. At data cutoff (Feb 24, 2022), 83 pts. (demographics are shown in Table 1) were available for efficacy and safety analysis...Confirmed ORR was 30.4% (95% confidence interval [CI]: 13.2, 52.9), with all seven patients achieving partial response. DCR was 78.3% (95% CI: 56.3, 92.5), median PFS was 5.4 months (95% CI: 2.8, 8.6), and median OS was not reached (95% CI: 6.7, not estimable).Sitravatinib plus tislelizumab demonstrated a manageable safety and tolerability profile as well as antitumor activity in patients with PD-L1+, locally advanced or metastatic squamous NSCLC who had not received prior systemic treatment in the metastatic setting.
Trial ID:
